Vertex Pharma (VRTX) Tops Q4 EPS by 8c, Offers Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Vertex Pharma (VRTX) Tops Q4 EPS by 8c, Offers Guidance

Vertex Reports Fourth Quarter 2021 and Full Year Financial Results

January 26, 2022 4:01 PM EST

-Full year product revenues of $7.57 billion, a 22% increase compared to full year 2020-

-Company provides full year 2022 product revenue guidance of $8.4 to $8.6 billion-

- Advancing broad clinical pipeline across six disease areas; multiple programs in mid- and late-stage development with clinical readouts expected in 2022-

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2021 and provided full year 2022 financial guidance.

"In 2021, Vertex delivered exceptional financial performance, including... More